Apimeds Proxy Sets Dec 23 Vote; Board Overhaul and Change of Control Loom
APUS is trading near its 52-week low of $1.51 (15% above the low) on light trading volume (0.1× avg).
Summary
Apimeds' definitive proxy sets the December 23 annual meeting and details a pending change of control: conversion of 7,477,017 non-voting preferred shares is expected to give Calfin Capital over 50% of voting power and reconstitute the board to seven seats.
Key Events · Corporate Governance and Compliance · APUS
-
Annual Meeting Set for December 23
The virtual 2026 Annual Meeting will be held on December 23, 2026 at 9:30 a.m. ET, with a record date of November 20, 2026. Four proposals are on the ballot: director election, auditor ratification, and adjournment.
-
Change of Control Pending Conversion
Upon NYSE American approval of the new listing application, 7,477,017 non-voting Series A preferred shares convert to common; Calfin Capital is expected to hold more than 50% of voting power, and the company may become a controlled company.
-
Board to Be Reconstituted
O'Donnell, Kogan and Weintraub are expected to resign at conversion, and the board expands to seven — four MindWave nominees, two Menon nominees (including Dr. Menon) and SungJoon Chae. The current board has four directors, three of them independent.
-
Auditor Ratification and Fees
Kreit & Chiu CPA LLP is up for ratification for FY2026; audit fees were $206,933 in 2025 versus $142,918 in 2024, with no audit-related or other fees.
Analysis · APUS · Life Sciences
On its face this definitive proxy is routine — elect four directors, ratify Kreit & Chiu, approve adjournment — but it hard-codes a governance reset that will hand control of the company to Calfin Capital. Once NYSE American approves the new listing application, the 7,477,017 non-voting Series A preferred shares convert to common, Calfin is expected to hold more than 50% of voting power, three of the four current independent directors (O'Donnell, Kogan, Weintraub) are expected to resign, and the board expands to seven: four MindWave nominees, two Menon nominees and Chae. That is a change of control and likely controlled-company status, meaning minority holders lose most board-level checks. The proxy also discloses that the $278,000 first installment of the $1,112,000 AQUAE Holdings related-party contract was still unpaid at September 30, 2026 — a related-party receivable booked with no revenue recognized. With only 1,847,626 common shares outstanding against 7,477,017 preferred, the conversion is the dominant fact for the equity story.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APUS was trading at $1.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $1.51 to $59.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.